as 03-28-2025 4:00pm EST
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 172.4M | IPO Year: | 2017 |
Target Price: | $4.33 | AVG Volume (30 days): | 5.6M |
Analyst Decision: | Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.42 | EPS Growth: | N/A |
52 Week Low/High: | $1.38 - $4.50 | Next Earning Date: | 03-28-2025 |
Revenue: | $41,000 | Revenue Growth: | -60.19% |
Revenue Growth (this year): | -86.46% | Revenue Growth (next year): | 300658.78% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Oliviero James F III | CKPT | CEO, President and Director | Feb 7 '25 | Sell | $3.28 | 19,564 | $64,027.18 | 3,785,350 | |
GRAY WILLIAM GARRETT | CKPT | Chief Financial Officer | Feb 6 '25 | Sell | $3.67 | 74,110 | $271,983.70 | 1,458,644 |
CKPT Breaking Stock News: Dive into CKPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Simply Wall St.
13 days ago
MT Newswires
18 days ago
MT Newswires
19 days ago
MT Newswires
19 days ago
MT Newswires
19 days ago
MT Newswires
19 days ago
Benzinga
19 days ago
The information presented on this page, "CKPT Checkpoint Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.